{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:12:32Z","timestamp":1777979552774,"version":"3.51.4"},"reference-count":23,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Neuromuscular disorders represent a diverse group of diseases mainly characterized by progressive or non-progressive muscle weakness [...]<\/jats:p>","DOI":"10.3390\/jcm15093523","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:01:30Z","timestamp":1777975290000},"page":"3523","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Care and Rehabilitation in Neuromuscular Disorders\u2014Why It Highly Matters"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0743-9670","authenticated-orcid":false,"given":"Hans-J\u00fcrgen","family":"Gdynia","sequence":"first","affiliation":[{"name":"Department of Neurology, m&i-Fachklinik Enzensberg, 87629 Hopfen am See, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/22143602241313118","article-title":"Prevalence and incidence rates of 17 neuromuscular disorders: An updated review of the literature","volume":"12","author":"Deenen","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ncl.2020.03.009","article-title":"Limb Girdle Muscular Dystrophies","volume":"38","author":"Bockhorst","year":"2020","journal-title":"Neurol. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10571-024-01511-3","article-title":"Spinal Muscular Atrophy: Current Medications and Re-purposed Drugs","volume":"44","author":"Basak","year":"2024","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Milisenda","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jama.2025.19400","article-title":"Peripheral Neuropathy: A Review","volume":"335","author":"Mauermann","year":"2026","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000488891","article-title":"Amyotrophic Lateral Sclerosis Mortality in the United States, 2011\u20132014","volume":"51","author":"Larson","year":"2018","journal-title":"Neuroepidemiology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"70586","DOI":"10.1111\/ene.70586","article-title":"Mortality from Amyotrophic Lateral Sclerosis in Finland 1987\u20132022","volume":"33","author":"Laine","year":"2026","journal-title":"Eur. J. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.nmd.2021.08.013","article-title":"Diagnostic delay in patients with FKRP-related muscular dystrophy","volume":"31","author":"Coffey","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Angilletta, I., Ferrante, R., Giansante, R., Lombardi, L., Babore, A., Dell\u2019elice, A., Alessandrelli, E., Notarangelo, S., Ranaudo, M., and Palmarini, C. (2023). Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914873"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.3233\/JND-210682","article-title":"Exon-Skipping in Duchenne Muscular Dystrophy","volume":"8","author":"Takeda","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"175675","DOI":"10.1016\/j.ejphar.2023.175675","article-title":"Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach","volume":"947","author":"Patterson","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s10072-025-07994-2","article-title":"Tofersen for SOD1 amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"46","author":"Hamad","year":"2025","journal-title":"Neurol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/j.ymthe.2021.04.008","article-title":"Gene therapy for ALS: A review","volume":"29","author":"Amado","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: The EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102495","DOI":"10.1016\/j.eclinm.2024.102495","article-title":"Effects of tofersen treatment in patients with SOD1-ALS in a \u201creal-world\u201d setting\u2014A 12-month multicenter cohort study from the German early access program","volume":"69","author":"Wiesenfarth","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e208112","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and Safety of Vamorolone Over 48 Weeks in Boys with Duchenne Muscular Dystrophy: A Randomized Controlled Trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e82833","DOI":"10.2196\/82833","article-title":"Developing, Implementing, and Evaluating a Care Management Model for Patients with Neuromuscular Diseases: Protocol for a Participatory Mixed Methods Study","volume":"15","author":"Waldboth","year":"2026","journal-title":"JMIR Res. Protoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e213781","DOI":"10.1212\/WNL.0000000000213781","article-title":"Efficacy of Combined Aerobic Exercise and Coaching on Physical Fitness in People with Neuromuscular Diseases: A Randomized Clinical Trial","volume":"105","author":"Oorschot","year":"2025","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Aksel Kilicarslan, O., Gangfu\u00df, A., K\u00f6lbel, H., Muhmann, D., Polavarapu, K., Thompson, R., Schmitt, L.-I., Lessard, L., Chen, L., and Eisenk\u00f6lbl, A. (2025). Combined Histological and Proteomic Analysis Reveals Muscle Denervation in KMT5B-Related Neurodevelopmental Disorder: A Case Report. J. Clin. Med., 14.","DOI":"10.3390\/jcm14248636"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Vianello, A., Guarnieri, G., Bertagna De Marchi, L., Molena, B., Arcaro, G., Capece, G., Sogus, E., Lionello, F., and Pegoraro, E. (2025). The Effect of Long-Term Non-Invasive Ventilation on Tracheostomy-Free Survival and Hospitalizations in Types 2 and 3 Spinal Muscular Atrophy Patients. J. Clin. Med., 14.","DOI":"10.3390\/jcm14228171"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Di Martino, G., Rini, N., Bonaventura, A., Trovato, M., Maccora, S., Lima, S.M., La Seta, C., Brighina, F., and Di Stefano, V. (2025). Complement Inhibitors in Generalized Myasthenia Gravis: Comparison of Administration Schedules, Efficacy, and Safety. J. Clin. Med., 14.","DOI":"10.3390\/jcm14228205"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"(2021). Gene therapy for spinal muscular atrophy: The benefit-cost profile. EClinicalMedicine, 37, 101065.","DOI":"10.1016\/j.eclinm.2021.101065"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3523\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:29:52Z","timestamp":1777976992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15093523"],"URL":"https:\/\/doi.org\/10.3390\/jcm15093523","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}